Tim D. Oury

Tim D. Oury, MD, PhD is a Professor of Pathology in the Division of Molecular & Genomic Pathology at the University of Pittsburgh School of Medicine. He is a physician-scientist with dual expertise in clinical molecular diagnostics and basic research on lung disease mechanisms. Dr. Oury co-directs a specialized program designed to transition physician-scientist trainees into academic faculty positions through combined Residency-Post-doctoral Research Fellowship or Residency-PhD tracks.

Dr. Oury's research program focuses on the role of the Receptor for Advanced Glycation Endproducts (RAGE) in respiratory diseases, particularly asthma pathogenesis. His laboratory discovered that RAGE is necessary for initiating innate immune responses that promote asthma development, specifically mediating lung-specific recruitment of group 2 innate lymphoid cells (ILC2) in response to allergens. His work extends to pulmonary fibrosis, oxidative stress mechanisms, and the role of extracellular superoxide dismutase in lung conditions.

Analysis of Dr. Oury's recent publications (2019-2024) reveals a continued focus on RAGE signaling in asthma and pulmonary fibrosis, with expanding research into viral respiratory infections and immune responses. His work spans basic molecular mechanisms, animal models, and translational applications, maintaining a strong presence in top respiratory and pathology journals.

As an educator and mentor, Dr. Oury plays a key role in developing the next generation of physician-scientists through his co-directorship of specialized training programs. His laboratory provides research opportunities investigating molecular mechanisms of lung disease with potential clinical applications.

Dr. Oury's laboratory investigates the molecular pathways connecting RAGE signaling with asthma development and pulmonary fibrosis, with particular emphasis on innate immune responses and cellular mechanisms in the lung. His work bridges basic science with clinical applications in molecular diagnostics and potential therapeutic targets for respiratory diseases.